{"data":{"id":"us/21-cfr-522.1850","jurisdiction":"us","citation":"21 CFR 522.1850","heading":"Polysulfated glycosaminoglycan.","body":"(a) Specifications. (1) Each 1-milliliter (mL) ampule of solution contains 250 milligrams (mg) polysulfated glycosaminoglycan.\n(2) Each mL of solution packaged in 5-mL ampules or 20-, 30-, or 50-mL vials contains 100 mg polysulfated glycosaminoglycan.\n(b) Sponsor. See No. 010797 in § 510.600(c) of this chapter.\n(c) Special considerations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.\n(d) Conditions of use—(1) Horses—(i) Indications for use. For the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.\n(ii) Amount—(A) Intra-articular use (carpal): 250 mg once a week for 5 weeks.\n(B) Intramuscular use (carpal and hock): 500 mg every 4 days for 28 days.\n(iii) Limitations. Do not use in horses intended for human consumption.\n(2) Dogs—(i) Indications for use. For control of signs associated with noninfectious degenerative and/or traumatic arthritis of canine synovial joints.\n(ii) Amount. 2 mg per pound of body weight by intramuscular injection twice weekly for up to 4 weeks (maximum of 8 injections).","path":["Title 21—Food and Drugs","CHAPTER I—FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES","SUBCHAPTER E—ANIMAL DRUGS, FEEDS, AND RELATED PRODUCTS","PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS"],"source_url":"https://www.ecfr.gov/api/versioner/v1/full/2026-08-25/title-21.xml","current_through":"2026-08-25","vintage":"","retrieved_at":"2026-08-27T02:24:47Z","sha256":"9d9361fd407efee1ddc968acd937e384d1a0e74014c204a7726721f2d214017f","source_id":"us-cfr","stale":true,"prev":"us/21-cfr-522.1820","next":"us/21-cfr-522.1860"},"notice":"GroundRules: Original legal text. Not legal advice."}